SNCE Fundamental Analysis - SCIENCE 37 HOLDINGS INC

Fundamental Rating

Overall SNCE gets a fundamental rating of 2 out of 10. We evaluated SNCE against 55 industry peers in the Life Sciences Tools & Services industry. While SNCE seems to be doing ok healthwise, there are quite some concerns on its profitability. SNCE is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

SNCE had negative earnings in the past year.

SNCE had a negative operating cash flow in the past year.

1.2 Ratios

SNCE has a worse Return On Assets (-164.66%) than 98.31% of its industry peers.

SNCE has a Return On Equity of -241.10%. This is amonst the worse of the industry: SNCE underperforms 88.14% of its industry peers.

		Industry Rank	Sector Rank
ROA	-164.66%
ROE	-241.1%
ROIC	N/A

ROA(3y)-44.02%

ROA(5y)N/A

ROE(3y)-71.84%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

SNCE has a worse Gross Margin (29.75%) than 72.88% of its industry peers.

The Profit Margin and Operating Margin are not available for SNCE so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	29.75%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

SNCE does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, SNCE has more shares outstanding

There is no outstanding debt for SNCE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -5.81, we must say that SNCE is in the distress zone and has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of -5.81, SNCE is doing worse than 93.22% of the companies in the same industry.

SNCE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-5.81

ROIC/WACCN/A

WACC11.9%

2.3 Liquidity

SNCE has a Current Ratio of 4.17. This indicates that SNCE is financially healthy and has no problem in meeting its short term obligations.

SNCE has a Current ratio of 4.17. This is in the better half of the industry: SNCE outperforms 62.71% of its industry peers.

SNCE has a Quick Ratio of 4.17. This indicates that SNCE is financially healthy and has no problem in meeting its short term obligations.

SNCE has a better Quick ratio (4.17) than 67.80% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	4.17
Quick Ratio	4.17

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for SNCE have decreased strongly by -881.08% in the last year.

The Revenue for SNCE has decreased by -19.21% in the past year. This is quite bad

EPS 1Y (TTM)-881.08%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-429.41%

Revenue 1Y (TTM)-19.21%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%-8.37%

3.2 Future

The Earnings Per Share is expected to decrease by -0.15% on average over the next years.

SNCE is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.73% yearly.

EPS Next Y-72.66%

EPS Next 2Y-1.9%

EPS Next 3Y-0.15%

EPS Next 5YN/A

Revenue Next Year-14.69%

Revenue Next 2Y-4.18%

Revenue Next 3Y3.19%

Revenue Next 5Y14.73%

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

SNCE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year SNCE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-1.9%

EPS Next 3Y-0.15%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

SNCE does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

SCIENCE 37 HOLDINGS INC

NASDAQ:SNCE (3/11/2024, 6:05:35 PM)

After market: 5.7203 -0.03 (-0.52%)

5.75

+0.02 (+0.35%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryLife Sciences Tools & Services

Earnings (Last)03-04 2024-03-04/amc

Earnings (Next)05-13 2024-05-13/bmo

Inst Owners0.02%

Inst Owner Change0%

Ins Owners287.18%

Ins Owner Change0%

Market Cap34.67M

Analysts76

Price Target14.11 (145.39%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)41.04%

Min EPS beat(2)36.97%

Max EPS beat(2)45.1%

EPS beat(4)4

Avg EPS beat(4)31.49%

Min EPS beat(4)21.57%

Max EPS beat(4)45.1%

EPS beat(8)7

Avg EPS beat(8)20.64%

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)1

Avg Revenue beat(2)9.12%

Min Revenue beat(2)-1.56%

Max Revenue beat(2)19.79%

Revenue beat(4)3

Avg Revenue beat(4)8.87%

Min Revenue beat(4)-1.56%

Max Revenue beat(4)19.79%

Revenue beat(8)5

Avg Revenue beat(8)8.69%

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)-51.88%

EPS NQ rev (1m)0%

EPS NQ rev (3m)-1950%

EPS NY rev (1m)0%

EPS NY rev (3m)-1907.14%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)0.48%

Revenue NY rev (1m)0%

Revenue NY rev (3m)0.12%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	0.58
P/FCF	N/A
P/OCF	N/A
P/B	0.67
P/tB	0.67
EV/EBITDA	N/A

EPS(TTM)-7.26

EYN/A

EPS(NY)-3.45

Fwd EYN/A

FCF(TTM)-12.22

FCFYN/A

OCF(TTM)-7.99

OCFYN/A

SpS10

BVpS8.57

TBVpS8.57

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-164.66%
ROE	-241.1%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	29.75%
FCFM	N/A

ROA(3y)-44.02%

ROA(5y)N/A

ROE(3y)-71.84%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score5

Asset Turnover0.8

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	432.94%
Cap/Sales	42.31%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	4.17
Quick Ratio	4.17
Altman-Z	-5.81

F-Score5

WACC11.9%

ROIC/WACCN/A

Cap/Depr(3y)193.38%

Cap/Depr(5y)N/A

Cap/Sales(3y)35.33%

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-881.08%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-429.41%

EPS Next Y-72.66%

EPS Next 2Y-1.9%

EPS Next 3Y-0.15%

EPS Next 5YN/A

Revenue 1Y (TTM)-19.21%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%-8.37%

Revenue Next Year-14.69%

Revenue Next 2Y-4.18%

Revenue Next 3Y3.19%

Revenue Next 5Y14.73%

EBIT growth 1Y48.62%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year61.54%

EBIT Next 3Y25.26%

EBIT Next 5Y19.21%

FCF growth 1Y-173.79%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-224.62%

OCF growth 3YN/A

OCF growth 5YN/A

SCIENCE 37 HOLDINGS INC (SNCE) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens